Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Happily, I was proven wrong.
It has begun to move. Possible big upside.
That spread's too big. I doubt anyone's going to bid over .06 . . . yet.
I heard a rumor this morning that if volume below .0139 exceeded 200k that the stock was going to get "run." With almost 600k traded, I don't see it.
Talk of trade wars and 5% tariff increase threatens the "trump rally" trending.
Me too.
The float is 52mil.
According to heritage.com, Beijing Bill and I are very distant cousins.
I have come to notice that those encouraging enthusiasm -- and ever-impending news -- have often been wrong in their prognostications.
Exactly what news or positive developments are you expecting to be released after the first of the year?
EDIT -- Just now seeing the news.
Give it all you got boys!
And what is going to happen on January 1?
Back to .0003, eh?
Hope you got rid of all your stock, Sil. Don't forget to donate a little of your profits to the charity of your choice.
I'm disappointed in you guys. I thought you could pump this higher. You did get it up from .0003 to .0016, so that's something, but I was expecting more. Can't you work it a little higher?
Was that it, Sil? Was that the pump? .0016 tops? Back to a tenth of a cent, or it looks like it will be even lower soon? I guess somebody cashed in, selling millions of shares over .001.
What's the news?
They must have discovered coal in Wyoming.
(I hope Santa didn't put it there.)
Navy to add destroyers and attack subs:
Navy Wants to Grow Fleet to 355 Ships; 47 Hull Increase Adds Destroyers, Attacks Subs
FMRC on a tear.
(That's a tare not a teer.)
Yeah yeah. When I look at level 2, I see a thinly traded microcap that's generating zero income, interest or buzz. Level two tells you nothing, and neither does the company.
There were virtually no contents to the press release, just the reiteration of the company's intentions.
The constant posting of immediately imminent news that doesn't come becomes questionable after a while. Someone seems more than happy to sell this stock at .0004, and I suspect it's for a reason.
No worries? There's been no news since their stock reverse split six months ago.
I can't count that high and lost track, do they have 9 billion shares outstanding, or is it 90 billion?
Could you be more specific about what kind of news is going to propel the price of this fairly dormant and inactive company?
I guess your humble opinion was off again. Want to venture when the next big news release comes?
The cheaper it goes, the better the bargain gets old after a while.
Without an update tomorrow morning, I predict a sell-off thanks to you guys.
Trading at 5.20 after hours.
Large tax cuts to corporations and the top 1% of the economy was proven ineffectual under both Reagan (who ultimately had to raise taxes to avoid a recession) and under GW Bush, who practically destroyed our economy with that trickle down eceonomics. How many times do Republicans have to fail with those shit policies before voters wake up? Poet laureate Bob Dylan sang that.
Relief from the fact that he tripled the DOW.
Trump rally? This is all just part of the Obama rally:
The DOW under Obama
Immune Pharmaceuticals CEO Talks Company And Its Recent Market Rally
Shares of Immune Pharmaceuticals Inc
IMNP 6.2%
were trending last week, gaining as much as 76 percent in three days. With no material news surfacing, it seemed like the rally was driven by a recent article that featured the company.
Shares have given up most of the gains on Thursday trading. However, they are still up almost 15 percent since Monday.
After the spike, Benzinga reached out to the company’s CEO Daniel G. Teper, Pharm.D., who shared some insight into the move, the stock and the company.
Getting Familiar With The Nano-Cap Company
Immune Pharma focuses on the application of immunology to treat autoimmune diseases and cancer, the chief executive explained. “Throughout the years, we built a very significant pipeline proactively, but also [...] when we made the reverse acquisition of a company [EpiCept Corporation] that led to our public listing.”
“Today Immune Pharmaceuticals remains a micro-cap company, even after the raise in the stock price in the last few days. It’s really four companies in one,” he explicated. “IMNP, the public company, will focus solely on the development of Bertilimumab, which is an antibody that had been developed originally by Cambridge Antibody Technology.”
And Bertilimumab
The company’s lead product candidate, Bertilimumab, is being developed to treat ulcerative colitis and bullous pemphigoid. Nonetheless, the company has also mentioned other potential indications including severe atopic dermatitis — an indication that has also been successfully pursued by Regeneron Pharmaceuticals Inc
REGN 4.74%
using a drug with a “distinct but similar method of action,” Crohn’s disease, several respiratory conditions, and non-alcoholic steatohepatitis (NASH).
“In addition to that, we’ve filed a patent, several months ago, on the oral administration of Bertilimumab for the treatment of NASH,” he added. “So, Bertilimumab is a very versatile target [...] you can look at in in two ways: You can look at Bertilimumab for specific orphan indications like bullous pemphigoid, and if the results of the Phase II are favorable, this is a program that we can take forward to Phase IIb, III, and potentially to commercialization; or you can look at it become an orphan dermatology company; or you can look at it more broadly and say that Bertilimumab has multiple indications, and is maybe more relevant in some than others [...] but it’s too early to say.”
“It’s really a pipeline drug that should be most attractive to big pharma companies or big biotech companies for further development,” he went on. “I think we’ll know that better some time in 2017, and if it’s the latter, which is basically an indication portfolio in a single drug, there’s a high probability that we’ll pursue discussions with big pharma companies to work for development or licensing of Bertilimumab.
“We don’t need the drug to be the best-in-class in every single indication to reach its full potential,” the exec concluded. “Actually, if only it shows efficacy in bullous pemphigoid, that, by itself, is an orphan indication where we could have sales between half a billion dollars and over a billion dollars with an accelerated development.”
The Stock Move
Finally, Benzinga asked about the recent spike in the stock price.
“The hypothesis is that our stock price has suffered from two major factors: The financings that the company had needed to do over the years, particularly the preferred financing in the summer of 2015, [which] was responsible for substantial dilution over time and selling pressure. In parallel to that, the company has had delays, one related to quality control in the manufacturing of Bertilimumab — which was then satisfactorily resolved — [...] but investors had expectations that we would move faster,” Teper voiced. “So, the combination of the aggressive financing with significant dilution and selling pressure, and the delays has driven the stock price down.”
“If you look at the situation today, we’ve got a clean cap table, there’s no more preferred shares; the investors from the summer of 2015 have essentially sold their shares, so there’s no more selling pressure; and from an operational standpoint, the team that was hired in early 2016 is now showing results [...] there is no more short-term financing because we completed a financing of $11 million from a single ‘friendly’ investor at market, so we can take money at market as needed [about $1 million or $2 million per month],” he added, assuring that all of this financing will be allocated to the development of Bertilimumab.
All the other assets will be distributed into three subsidiaries with promising prospects, which provide further opportunities for Immune Pharmaceuticals shareholders, he concluded.
ARTICLE
Immune Pharmaceuticals CEO Talks Company And Its Recent Market Rally
Shares of Immune Pharmaceuticals Inc
IMNP 6.2%
were trending last week, gaining as much as 76 percent in three days. With no material news surfacing, it seemed like the rally was driven by a recent article that featured the company.
Shares have given up most of the gains on Thursday trading. However, they are still up almost 15 percent since Monday.
After the spike, Benzinga reached out to the company’s CEO Daniel G. Teper, Pharm.D., who shared some insight into the move, the stock and the company.
Getting Familiar With The Nano-Cap Company
Immune Pharma focuses on the application of immunology to treat autoimmune diseases and cancer, the chief executive explained. “Throughout the years, we built a very significant pipeline proactively, but also [...] when we made the reverse acquisition of a company [EpiCept Corporation] that led to our public listing.”
“Today Immune Pharmaceuticals remains a micro-cap company, even after the raise in the stock price in the last few days. It’s really four companies in one,” he explicated. “IMNP, the public company, will focus solely on the development of Bertilimumab, which is an antibody that had been developed originally by Cambridge Antibody Technology.”
And Bertilimumab
The company’s lead product candidate, Bertilimumab, is being developed to treat ulcerative colitis and bullous pemphigoid. Nonetheless, the company has also mentioned other potential indications including severe atopic dermatitis — an indication that has also been successfully pursued by Regeneron Pharmaceuticals Inc
REGN 4.74%
using a drug with a “distinct but similar method of action,” Crohn’s disease, several respiratory conditions, and non-alcoholic steatohepatitis (NASH).
“In addition to that, we’ve filed a patent, several months ago, on the oral administration of Bertilimumab for the treatment of NASH,” he added. “So, Bertilimumab is a very versatile target [...] you can look at in in two ways: You can look at Bertilimumab for specific orphan indications like bullous pemphigoid, and if the results of the Phase II are favorable, this is a program that we can take forward to Phase IIb, III, and potentially to commercialization; or you can look at it become an orphan dermatology company; or you can look at it more broadly and say that Bertilimumab has multiple indications, and is maybe more relevant in some than others [...] but it’s too early to say.”
“It’s really a pipeline drug that should be most attractive to big pharma companies or big biotech companies for further development,” he went on. “I think we’ll know that better some time in 2017, and if it’s the latter, which is basically an indication portfolio in a single drug, there’s a high probability that we’ll pursue discussions with big pharma companies to work for development or licensing of Bertilimumab.
“We don’t need the drug to be the best-in-class in every single indication to reach its full potential,” the exec concluded. “Actually, if only it shows efficacy in bullous pemphigoid, that, by itself, is an orphan indication where we could have sales between half a billion dollars and over a billion dollars with an accelerated development.”
The Stock Move
Finally, Benzinga asked about the recent spike in the stock price.
“The hypothesis is that our stock price has suffered from two major factors: The financings that the company had needed to do over the years, particularly the preferred financing in the summer of 2015, [which] was responsible for substantial dilution over time and selling pressure. In parallel to that, the company has had delays, one related to quality control in the manufacturing of Bertilimumab — which was then satisfactorily resolved — [...] but investors had expectations that we would move faster,” Teper voiced. “So, the combination of the aggressive financing with significant dilution and selling pressure, and the delays has driven the stock price down.”
“If you look at the situation today, we’ve got a clean cap table, there’s no more preferred shares; the investors from the summer of 2015 have essentially sold their shares, so there’s no more selling pressure; and from an operational standpoint, the team that was hired in early 2016 is now showing results [...] there is no more short-term financing because we completed a financing of $11 million from a single ‘friendly’ investor at market, so we can take money at market as needed [about $1 million or $2 million per month],” he added, assuring that all of this financing will be allocated to the development of Bertilimumab.
All the other assets will be distributed into three subsidiaries with promising prospects, which provide further opportunities for Immune Pharmaceuticals shareholders, he concluded.
ARTICLE
OT (Weekend): Actually, Trump is inheriting a pretty strong economy, nothing like the chaos Obama inherited and brought us out of eight years ago.
While everyone is doing cartwheels over the "Trump rally" and the DOW highs, I don't remember everyone being so excited about the highs the DOW was at before Trump eked out an electoral college vicotry. Let's also not forget, Obama is still POTUS and the country it is still under the influence of his economic policies, not the exaggerations of Trumps Carrier deal (bribery).
And bbots . . . The US has a debt, but it doesn't have an "insane deficit." Obama has bought the deficit down. Watch it soar to insane heights again when he cuts taxes to 1%.
Partisanship is a bit inevitable, but we needn't indulge delusions.
Hey Baulsdp . . . . How do you see this playing out over the next few days? TIA . . .
Delusions beget themselves. Adios.
The actual story that you quoted is that ISIS is losing territory in the Middle East. They claim to be a state, and thanks to allied forces, led by President Barack Obama, their stronghold has been broken.
The threat to unleash "lone wolves" in the west is to scare cowards. That's the meaning of "terrorism," basserdan.
Just like Trump is trying to take credit for the lowest unemployment number and the highest DOW since 2007, the credit goes to Obama, not President Elect Blow Hard.
How do we know? TIA
How many times can a man turn his head and pretend that he just doesn't see?